Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha: Risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years

Hyun Jung Lee, Jong Eun Yeon, Eileen L. Yoon, Sang Jun Suh, Keunhee Kang, Hae Rim Kim, Seong Hee Kang, Yang Jae Yoo, Jihye Je, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun

Research output: Contribution to journalArticle

Abstract

Objectives: Interferon (IFN)-based therapy for chronic hepatitis C (CHC) is cost-effective and is associated with reduced risk of disease progression. We aimed to assess the incidence of cirrhosis and hepatocellular carcinoma (HCC) and to identify risk factors associated with disease progression. Methods: We retrospectively reviewed 280 CHC patients who were registered at our hospital between 2001 and 2010. Results: About 80% of patients received antiviral treatment. The 10-year cumulative incidence of cirrhosis was significantly lower among patients who received antiviral therapy than among those who did not (8.3 vs. 44.0%; p = 0.001). Among them, patients with sustained virological response (SVR) had a significantly lower incidence of cirrhosis than those without SVR (0.6 vs. 33.9%; p < 0.001). Cox proportional hazards regression showed that SVR was the significant independent factor for reducing the risk of cirrhosis (hazard ratio, HR = 0.03; p = 0.034). The 10-year cumulative incidence of HCC was higher among patients who did not receive antiviral therapy than among those who did (43.9 vs. 6.1%; p < 0.001). Multivariate analysis showed that underlying cirrhosis was the only independent risk factor associated with HCC development (HR = 7.70; p = 0.010). Conclusions: SVR secondary to IFN-based therapy could reduce cirrhosis development in CHC patients. Underlying cirrhosis was the strongest predictor of HCC development.

Original languageEnglish
Pages (from-to)14-21
Number of pages8
JournalIntervirology
Volume58
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Chronic Hepatitis C
Interferon-alpha
Hepatocellular Carcinoma
Fibrosis
Antiviral Agents
Incidence
Interferons
Disease Progression
Therapeutics
Multivariate Analysis
Costs and Cost Analysis

Keywords

  • Chronic hepatitis C
  • Cirrhosis
  • Hepatocellular carcinoma
  • Interferon
  • Sustained virological response

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha : Risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years. / Lee, Hyun Jung; Yeon, Jong Eun; Yoon, Eileen L.; Suh, Sang Jun; Kang, Keunhee; Kim, Hae Rim; Kang, Seong Hee; Yoo, Yang Jae; Je, Jihye; Kim, Ji Hoon; Seo, Yeon Seok; Yim, Hyung Joon; Byun, Kwan Soo.

In: Intervirology, Vol. 58, No. 1, 01.01.2015, p. 14-21.

Research output: Contribution to journalArticle

@article{47e8fc0da58d4a18a18df34bceaa29d1,
title = "Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha: Risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years",
abstract = "Objectives: Interferon (IFN)-based therapy for chronic hepatitis C (CHC) is cost-effective and is associated with reduced risk of disease progression. We aimed to assess the incidence of cirrhosis and hepatocellular carcinoma (HCC) and to identify risk factors associated with disease progression. Methods: We retrospectively reviewed 280 CHC patients who were registered at our hospital between 2001 and 2010. Results: About 80{\%} of patients received antiviral treatment. The 10-year cumulative incidence of cirrhosis was significantly lower among patients who received antiviral therapy than among those who did not (8.3 vs. 44.0{\%}; p = 0.001). Among them, patients with sustained virological response (SVR) had a significantly lower incidence of cirrhosis than those without SVR (0.6 vs. 33.9{\%}; p < 0.001). Cox proportional hazards regression showed that SVR was the significant independent factor for reducing the risk of cirrhosis (hazard ratio, HR = 0.03; p = 0.034). The 10-year cumulative incidence of HCC was higher among patients who did not receive antiviral therapy than among those who did (43.9 vs. 6.1{\%}; p < 0.001). Multivariate analysis showed that underlying cirrhosis was the only independent risk factor associated with HCC development (HR = 7.70; p = 0.010). Conclusions: SVR secondary to IFN-based therapy could reduce cirrhosis development in CHC patients. Underlying cirrhosis was the strongest predictor of HCC development.",
keywords = "Chronic hepatitis C, Cirrhosis, Hepatocellular carcinoma, Interferon, Sustained virological response",
author = "Lee, {Hyun Jung} and Yeon, {Jong Eun} and Yoon, {Eileen L.} and Suh, {Sang Jun} and Keunhee Kang and Kim, {Hae Rim} and Kang, {Seong Hee} and Yoo, {Yang Jae} and Jihye Je and Kim, {Ji Hoon} and Seo, {Yeon Seok} and Yim, {Hyung Joon} and Byun, {Kwan Soo}",
year = "2015",
month = "1",
day = "1",
doi = "10.1159/000369206",
language = "English",
volume = "58",
pages = "14--21",
journal = "Intervirology",
issn = "0300-5526",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha

T2 - Risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years

AU - Lee, Hyun Jung

AU - Yeon, Jong Eun

AU - Yoon, Eileen L.

AU - Suh, Sang Jun

AU - Kang, Keunhee

AU - Kim, Hae Rim

AU - Kang, Seong Hee

AU - Yoo, Yang Jae

AU - Je, Jihye

AU - Kim, Ji Hoon

AU - Seo, Yeon Seok

AU - Yim, Hyung Joon

AU - Byun, Kwan Soo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: Interferon (IFN)-based therapy for chronic hepatitis C (CHC) is cost-effective and is associated with reduced risk of disease progression. We aimed to assess the incidence of cirrhosis and hepatocellular carcinoma (HCC) and to identify risk factors associated with disease progression. Methods: We retrospectively reviewed 280 CHC patients who were registered at our hospital between 2001 and 2010. Results: About 80% of patients received antiviral treatment. The 10-year cumulative incidence of cirrhosis was significantly lower among patients who received antiviral therapy than among those who did not (8.3 vs. 44.0%; p = 0.001). Among them, patients with sustained virological response (SVR) had a significantly lower incidence of cirrhosis than those without SVR (0.6 vs. 33.9%; p < 0.001). Cox proportional hazards regression showed that SVR was the significant independent factor for reducing the risk of cirrhosis (hazard ratio, HR = 0.03; p = 0.034). The 10-year cumulative incidence of HCC was higher among patients who did not receive antiviral therapy than among those who did (43.9 vs. 6.1%; p < 0.001). Multivariate analysis showed that underlying cirrhosis was the only independent risk factor associated with HCC development (HR = 7.70; p = 0.010). Conclusions: SVR secondary to IFN-based therapy could reduce cirrhosis development in CHC patients. Underlying cirrhosis was the strongest predictor of HCC development.

AB - Objectives: Interferon (IFN)-based therapy for chronic hepatitis C (CHC) is cost-effective and is associated with reduced risk of disease progression. We aimed to assess the incidence of cirrhosis and hepatocellular carcinoma (HCC) and to identify risk factors associated with disease progression. Methods: We retrospectively reviewed 280 CHC patients who were registered at our hospital between 2001 and 2010. Results: About 80% of patients received antiviral treatment. The 10-year cumulative incidence of cirrhosis was significantly lower among patients who received antiviral therapy than among those who did not (8.3 vs. 44.0%; p = 0.001). Among them, patients with sustained virological response (SVR) had a significantly lower incidence of cirrhosis than those without SVR (0.6 vs. 33.9%; p < 0.001). Cox proportional hazards regression showed that SVR was the significant independent factor for reducing the risk of cirrhosis (hazard ratio, HR = 0.03; p = 0.034). The 10-year cumulative incidence of HCC was higher among patients who did not receive antiviral therapy than among those who did (43.9 vs. 6.1%; p < 0.001). Multivariate analysis showed that underlying cirrhosis was the only independent risk factor associated with HCC development (HR = 7.70; p = 0.010). Conclusions: SVR secondary to IFN-based therapy could reduce cirrhosis development in CHC patients. Underlying cirrhosis was the strongest predictor of HCC development.

KW - Chronic hepatitis C

KW - Cirrhosis

KW - Hepatocellular carcinoma

KW - Interferon

KW - Sustained virological response

UR - http://www.scopus.com/inward/record.url?scp=84921357817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921357817&partnerID=8YFLogxK

U2 - 10.1159/000369206

DO - 10.1159/000369206

M3 - Article

C2 - 25592614

AN - SCOPUS:84921357817

VL - 58

SP - 14

EP - 21

JO - Intervirology

JF - Intervirology

SN - 0300-5526

IS - 1

ER -